Sana Biotechnology logo
SANASana Biotechnology
Trade SANA now
Sana Biotechnology primary media

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) focuses on creating and delivering engineered cells as medicines for patients. They're deeply invested in developing therapies that touch on a wide range of medical areas, including oncology, diabetes, central nervous system disorders, and cardiovascular diseases. Their projects harness cutting-edge technology to modify the fundamental building blocks of life with the aim to treat, and potentially cure, debilitating medical conditions. With an innovative spirit at its core, Sana is dedicated to pushing the boundaries of medicine, striving to bring transformative and accessible treatments to people around the world. Their objectives are clear: innovate in the medical field, ensure treatments are patient-centric, and achieve lasting solutions to complex diseases.

What is SANA known for?

Snapshot

Public US
Ownership
2018
Year founded
365
Employees
Seattle, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Seattle, US

Products and/or services of Sana Biotechnology

  • In Vivo Cell Engineering platform aiming to repair and control genes in patients' cells for a wide range of diseases.
  • Ex Vivo Gene Correction technologies focused on editing cells outside the body then transplanting them back to treat genetic disorders.
  • CAR-T therapy development for cancer treatment, leveraging innovative cell engineering to enhance efficacy and safety.
  • Hypoimmune Platform designed to create universally compatible cells resistant to immune rejection, advancing organ transplantation and cell therapies.
  • Manufacturing and scale-up processes for producing high-quality, scalable cell and gene therapy products efficiently.

Sana Biotechnology executive team

  • Dr. Steven D. Harr M.D.President, CEO & Director
  • Ms. Susan WyrickActing CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting
  • Mr. Snehal PatelSenior VP & Chief Technical Officer
  • Dr. Dhavalkumar D. Patel M.D., Ph.D.Executive VP & Chief Scientific Officer
  • Mr. Aaron M. GrossmanExecutive VP & Chief Legal Officer
  • Dr. Gary Meininger M.D.Chief Medical Officer
  • Dr. Yuko Soneoka J.D., Ph.D.Head of Intellectual Property
  • Mr. John Gerecitano M.D., Ph.D.Head of Oncology Research & Development

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.